surmount-1 trial tirzepatide non-diabetic obesity weight loss after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 🤔Adults with type 2 diabetes

Understanding these interactions prevents inadvertent side effects and maximizes the benefits of your routine

These effects make it a poor candidate for injection formulations where you want minimal additional side effects on top of semaglutide GI symptoms

CT-868 is an injectable GLP-1/GIP dual agonist in development as an adjunct therapy to insulin for T1D

As a long acting GLP-1 RA, semaglutide can translocate to the brain stem, lateral septum (LS), and hypothalamus, interact directly with various GLP-1 receptor subtypes and modulate the activity of neural pathways involved in food intake, reward, and energy expenditure (19, 20)